(Q37890244)

24 August 2017

1 reference

title

T-cell receptor gene therapy: critical parameters for clinical success (English)

1 reference

24 August 2017

0 references

Carsten Linnemann

1 reference

24 August 2017

Ton N M Schumacher

series ordinal

1 reference

24 August 2017

Gavin M Bendle

series ordinal

1 reference

24 August 2017

language of work or name

English

0 references

publication date

16 June 2011

1 reference

Journal of Investigative Dermatology

24 August 2017

published in

1 reference

24 August 2017

volume

131

1 reference

24 August 2017

1 reference

24 August 2017

page(s)

1806-1816

1 reference

Preclinical development of T cell receptor gene therapy

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Induction of unresponsiveness limits tumor protection by adoptively transferred MDM2-specific cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

A study of T cell tolerance to the tumor-associated antigen MDM2: cytokines can restore antigen responsiveness, but not high avidity T cell function

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Signatures of mutation and selection in the cancer genome

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Cancer/testis (CT) antigens: potential targets for immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Potentiation of tumor eradication by adoptive immunotherapy with T-cell receptor gene-transduced T-helper type 1 cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Can the low-avidity self-specific T cell repertoire be exploited for tumor rejection?

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Targeting self-antigens through allogeneic TCR gene transfer

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Requirements for effective antitumor responses of TCR transduced T cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Transfer of specificity by murine alpha and beta T-cell receptor genes

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

In vitro evolution of a T cell receptor with high affinity for peptide/MHC.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Generation of T cell help through a MHC class I-restricted TCR.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Changing T cell specificity by retroviral T cell receptor display

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Immunotherapy through TCR gene transfer

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Facilitating matched pairing and expression of TCR chains introduced into human T cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

A flexible multiplex bead-based assay for detecting germline CDKN2A and CDK4 variants in melanoma-prone kindreds

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

The response of autologous T cells to a human melanoma is dominated by mutated neoantigens

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Identification of pancreatic cancer stem cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Transgenic mice with a diverse human T cell antigen receptor repertoire.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Directed evolution of human T-cell receptors with picomolar affinities by phage display.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Prostate cancer stem cells: a new target for therapy

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Sequencing technologies - the next generation

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Cancer regression in patients after transfer of genetically engineered lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Simultaneous detection of many T-cell specificities using combinatorial tetramer staining.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

A human colon cancer cell capable of initiating tumour growth in immunodeficient mice

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Antigen choice in adoptive T-cell therapy of cancer

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Generation of multi-functional antigen-specific human T-cells by lentiviral TCR gene transfer

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

cDNA and protein characterization of human MAGE-10

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Of Mice, Not Men: No Evidence for Graft-versus-Host Disease in Humans Receiving T-Cell Receptor–Transduced Autologous T Cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Identification of cells initiating human melanomas

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

The transfer of adaptive immunity to CMV during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T cells in the donor

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

MAGE-A10 is a nuclear protein frequently expressed in high percentages of tumor cells in lung, skin and urothelial malignancies.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

T-cell-receptor gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Cancer/testis antigens, gametogenesis and cancer

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Designer T cells by T cell receptor replacement.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Therapeutic cell engineering with surface-conjugated synthetic nanoparticles

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Reconstitution of CD8+ T cells by retroviral transfer of the TCR alpha beta-chain genes isolated from a clonally expanded P815-infiltrating lymphocyte.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Design and use of conditional MHC class I ligands.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

TCR transgenes and transgene cassettes for TCR gene therapy: status in 2008.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Mixed T cell receptor dimers harbor potentially harmful neoreactivity

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

A census of predicted mutational epitopes suitable for immunologic cancer control.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Transforming growth factor-beta and the immune response: implications for anticancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

A simplified method for the clinical-scale generation of central memory-like CD8+ T cells after transduction with lentiviral vectors encoding antitumor antigen T-cell receptors.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.160

7 January 2021

Identifiers

DOI

10.1038/JID.2011.160

1 reference

24 August 2017

1 reference